Format

Send to

Choose Destination
See comment in PubMed Commons below
Pharm Res. 2007 Feb;24(2):228-38. Epub 2006 Dec 19.

Gene therapy of the other genome: the challenges of treating mitochondrial DNA defects.

Author information

  • 1BouvĂ© College of Health Sciences, Department of Pharmaceutical Sciences, Northeastern University, 360 Huntington Avenue, 211 Mugar Building, Boston, Massachusetts 02115, USA.

Abstract

Human mitochondrial DNA is a 16.5 kb circular DNA molecule located inside the mitochondrial matrix. Although accounting for only about 1% of total cellular DNA, defects in mitochondrial DNA have been found to have major effects on human health. A single mtDNA mutation may cause a bewildering variety of clinical symptoms mainly involving the neuromuscular system at any age of onset. Despite significant advances in the understanding of mitochondrial DNA defects at a molecular level, the clinical diagnosis of mtDNA diseases remains a significant challenge and effective therapies for such diseases are as yet unavailable. In contrast to gene therapy for chromosomal DNA defects, mitochondrial gene therapy is a field that is still in its infancy and attempts towards gene therapy of the mitochondrial genome are rare. In this review we outline what we believe are the unique challenges associated with the correction of mtDNA mutations and summarize current approaches to gene therapy for the "other genome".

PMID:
17180727
DOI:
10.1007/s11095-006-9150-y
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Support Center